AR067977A1 - Derivados de piridina y su uso como inmunomoduladores - Google Patents
Derivados de piridina y su uso como inmunomoduladoresInfo
- Publication number
- AR067977A1 AR067977A1 ARP080103611A ARP080103611A AR067977A1 AR 067977 A1 AR067977 A1 AR 067977A1 AR P080103611 A ARP080103611 A AR P080103611A AR P080103611 A ARP080103611 A AR P080103611A AR 067977 A1 AR067977 A1 AR 067977A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- compound
- methoxy
- attached
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
Dichos compuestos actuan particularmente como agentes inmunomoduladores. Reivindicacion 1: Un compuesto de formula (1), Piridina1-A-Piridiria2, donde Piridina1 representa un compuesto del grupo de formulas (2) donde los asteriscos marcan el enlace con el cual el anillo de Piridina1 está unido a A; R1 representa alquilo C1-5, alcoxi C1-4, cicloalquilo C3-6, hidroximetilo, o NR1aR1b; R1a representa alquilo C1-4, R1b representa hidrogeno, o alquilo C1-3, o R1a y R1b, junto con el nitrogeno que está unido a la piridina, forman un anillo de pirrolidina; R2 representa hidrogeno, o alquilo C1-4, o en el caso en que R1 represente alquilo C1-5 o cicIoalquilo C3-6, R2 puede representar además rnetoxi; R3 representa alquilo C1-5, alcoxi C1-4, cicloalquilo C3-6, o NR3aR3b; R3a representa alquilo C1-4; R3b representa H, o alquilo C1-3; R4 representa alquilo C1-4, o H; R5 representa alquilo C1-5, metoxi, o NR5aR5b; y R6 representa alquilo C1-2; R5a representa alquilo C1-4; R5b representa H, o alquilo C1-3; o R5 representa alquilo C1-2, o metoxi; y R6 representa alquilo C1-5, o NR6aR6b; R6a representa alquilo C1-4; R6b representa hidrogeno, o alquilo C1-3; R7 representa alquilo C1-5; R8 representa alquilo C1-2, o metoxi; R9 representa alquilo C1-5; R10 representa alquilo C1-2; A representa un compuesto del grupo de las formulas (3), donde los asteriscos indican el enlace que está unido al anillo de Piridina1; Piridina2 representa un compuesto del grupo de formulas (4), donde los asteriscos marcan el enlace con el cual el anillo de Piridina2 está unido a A; R11 representa alquilo C1-4, alcoxi C1-3, hidroximetilo, o NR11aR11b; R11a representa alquilo C1-3, R11b representa hidrogeno, o alquilo C1-2, R12 representa hidrogeno, o alquilo C1-2, R13 representa alquilo C1-4, o representa NR13aR13b; R13a representa alquilo C1-3; R13b representa hidrogeno, o alquilo C1-2, R14 representa alquilo C1-2; R15 representa alquilo C1-4, o NR15aR15b; y R16 representa alquilo C1-2; R15a representa alquilo C1-3, R15b representa hidrogeno, o alquilo C1-3; o R15 representa alquilo C1-2; y R16 representa alquilo C1-4, o NR16aR16b; R16a representa alquilo C1-3; R16b representa hidrogeno, o alquilo C1-2; R17 representa alquilo C1-4; R18 representa alquilo C1-2, o metoxi; R19 representa alquilo C1-4; y R20 representa alquilo C1-2; con la excepcion de 3-(2-etil-4-piridil)-5-(2-etil-4-piridil)-1,2,4-oxadiazol; o una sal de dicho compuesto.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2007053293 | 2007-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067977A1 true AR067977A1 (es) | 2009-10-28 |
Family
ID=40193868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103611A AR067977A1 (es) | 2007-08-17 | 2008-08-19 | Derivados de piridina y su uso como inmunomoduladores |
Country Status (27)
Country | Link |
---|---|
US (1) | US8598208B2 (es) |
EP (1) | EP2195311B1 (es) |
JP (1) | JP5451614B2 (es) |
KR (1) | KR101541558B1 (es) |
CN (1) | CN102648198B (es) |
AR (1) | AR067977A1 (es) |
AT (1) | ATE502938T1 (es) |
AU (1) | AU2008290233B2 (es) |
BR (1) | BRPI0815190A2 (es) |
CA (1) | CA2695509A1 (es) |
CY (1) | CY1111830T1 (es) |
DE (1) | DE602008005770D1 (es) |
DK (1) | DK2195311T3 (es) |
ES (1) | ES2361463T3 (es) |
HK (1) | HK1144809A1 (es) |
HR (1) | HRP20110449T1 (es) |
MA (1) | MA31703B1 (es) |
MX (1) | MX2010001881A (es) |
MY (1) | MY153975A (es) |
NZ (1) | NZ583957A (es) |
PL (1) | PL2195311T3 (es) |
PT (1) | PT2195311E (es) |
RU (1) | RU2492168C2 (es) |
SI (1) | SI2195311T1 (es) |
TW (1) | TWI422373B (es) |
WO (1) | WO2009024905A1 (es) |
ZA (1) | ZA201001873B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007292993B2 (en) * | 2006-09-07 | 2013-01-24 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
CA2661315C (en) | 2006-09-08 | 2015-11-24 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
CA2667545A1 (en) * | 2006-10-25 | 2008-05-02 | Neurosearch A/S | Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators |
DK2125797T3 (da) * | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
SI2252609T1 (sl) * | 2008-03-07 | 2013-07-31 | Actelion Pharmaceuticals Ltd. | Derivati piridin-2-ila kot imunomodulacijska sredstva |
WO2009115954A1 (en) | 2008-03-17 | 2009-09-24 | Actelion Pharmaceuticals Ltd | Dosing regimen for a selective s1p1 receptor agonist |
SG175855A1 (en) * | 2009-05-04 | 2011-12-29 | Prometic Biosciences Inc | Substituted aromatic compounds and pharmaceutical uses thereof |
TWI410421B (zh) | 2009-07-16 | 2013-10-01 | Actelion Pharmaceuticals Ltd | 吡啶-4-基衍生物 |
AU2012208325B2 (en) | 2011-01-19 | 2016-12-22 | Idorsia Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
EP2844655A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyridine compounds as crac modulators |
PT2885266T (pt) | 2012-08-17 | 2020-05-29 | Actelion Pharmaceuticals Ltd | Processo para a preparação de (2z,5z)-5-(3-cloro-4-((r)-2,3-di-hidropropoxi)benzilideno)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona e intermediário utilizado no referido processo |
KR102212975B1 (ko) | 2013-03-15 | 2021-02-05 | 이도르시아 파마슈티컬스 리미티드 | 피리딘-4-일 유도체 |
CN114573574A (zh) | 2015-05-20 | 2022-06-03 | 爱杜西亚药品有限公司 | 一种化合物的结晶形式 |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
WO2017004610A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Tercyclic s1p3-sparing, s1p1 receptor agonists |
WO2017004608A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Oxadiazole modulators of s1p methods of making and using |
WO2017004609A1 (en) | 2015-07-02 | 2017-01-05 | Exelixis, Inc. | Thiadiazole modulators of s1p and methods of making and using |
CN109069514B (zh) | 2016-03-07 | 2023-12-29 | 结核病药物开发全球联盟公司 | 抗菌化合物及其用途 |
WO2017157885A1 (de) | 2016-03-16 | 2017-09-21 | Bayer Cropscience Aktiengesellschaft | N-(cyanbenzyl)-6-(cyclopropylcarbonylamino)-4-(phenyl)-pyridin-2-carboxamid-derivate und verwandte verbindungen als pestizide pflanzenschutzmittel |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US20240018106A1 (en) * | 2020-09-11 | 2024-01-18 | Pi Industries Ltd. | A process for the preparation of substituted pyridine compounds and intermediates thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3647809A (en) * | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
WO1999046277A1 (en) | 1998-03-09 | 1999-09-16 | Smithkline Beecham Corporation | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE |
DK1210344T3 (da) | 1999-08-19 | 2006-03-06 | Nps Pharma Inc | Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister |
NZ527691A (en) | 2001-02-21 | 2007-01-26 | Nps Pharma Inc | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
US7479504B2 (en) | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
AU2003279915A1 (en) | 2002-10-15 | 2004-05-04 | Merck And Co., Inc. | Process for making azetidine-3-carboxylic acid |
US20060252741A1 (en) | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
CN1859908A (zh) | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5-芳基、杂芳基或环烷基取代的-1,2,4-噁二唑类化合物 |
JP4773972B2 (ja) * | 2003-12-17 | 2011-09-14 | メルク・シャープ・エンド・ドーム・コーポレイション | S1P(Edg)受容体作働薬としての(3,4−ジ置換)プロパンカルボン酸 |
US8022063B2 (en) | 2004-05-29 | 2011-09-20 | 7Tm Pharma A/S | CRTH2 receptor ligands for medicinal uses |
CN101160285A (zh) | 2005-03-17 | 2008-04-09 | 辉瑞大药厂 | 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物 |
AU2006239418A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
AU2006256968A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands |
US20090054491A1 (en) | 2005-06-28 | 2009-02-26 | Astrazeneca Ab | Use |
TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
EP1979345B1 (en) * | 2006-01-24 | 2009-11-04 | Actelion Pharmaceuticals Ltd. | Novel pyridine derivatives |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
AU2007292993B2 (en) * | 2006-09-07 | 2013-01-24 | Idorsia Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
CA2661315C (en) * | 2006-09-08 | 2015-11-24 | Actelion Pharmaceuticals Ltd | Pyridin-3-yl derivatives as immunomodulating agents |
RU2442780C2 (ru) * | 2006-09-21 | 2012-02-20 | Актелион Фармасьютиклз Лтд | Фенильные производные и их применение в качестве иммуномодуляторов |
AU2007334436A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
DK2125797T3 (da) * | 2007-03-16 | 2014-02-10 | Actelion Pharmaceuticals Ltd | Aminopyridinderivater som s1p1/edg1-receptoragonister |
AU2008320374A1 (en) * | 2007-11-01 | 2009-05-07 | Actelion Pharmaceuticals Ltd | Novel pyrimidine derivatives |
JP2011513385A (ja) * | 2008-03-06 | 2011-04-28 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピリミジン−ピリジン誘導体 |
ES2389042T3 (es) * | 2008-03-06 | 2012-10-22 | Actelion Pharmaceuticals Ltd. | Compuestos de piridina |
US8410151B2 (en) * | 2008-03-07 | 2013-04-02 | Actelion Pharmaceuticals Ltd | Aminomethyl benzene derivatives |
SI2252609T1 (sl) * | 2008-03-07 | 2013-07-31 | Actelion Pharmaceuticals Ltd. | Derivati piridin-2-ila kot imunomodulacijska sredstva |
NZ589617A (en) | 2008-05-14 | 2012-06-29 | Scripps Research Inst | 3-(Inden-4-yl)-5-(phenyl)-1,2,4-oxadiazole and 3-(tetralin-5-yl)-5-(phenyl)-1,2,4-oxadiazole derivatives |
TWI410421B (zh) * | 2009-07-16 | 2013-10-01 | Actelion Pharmaceuticals Ltd | 吡啶-4-基衍生物 |
-
2008
- 2008-08-14 SI SI200830269T patent/SI2195311T1/sl unknown
- 2008-08-14 PT PT08789611T patent/PT2195311E/pt unknown
- 2008-08-14 BR BRPI0815190 patent/BRPI0815190A2/pt not_active IP Right Cessation
- 2008-08-14 CN CN200880103070.2A patent/CN102648198B/zh not_active Expired - Fee Related
- 2008-08-14 WO PCT/IB2008/053269 patent/WO2009024905A1/en active Application Filing
- 2008-08-14 US US12/673,918 patent/US8598208B2/en not_active Expired - Fee Related
- 2008-08-14 EP EP08789611A patent/EP2195311B1/en not_active Not-in-force
- 2008-08-14 AU AU2008290233A patent/AU2008290233B2/en not_active Ceased
- 2008-08-14 AT AT08789611T patent/ATE502938T1/de active
- 2008-08-14 KR KR1020107005759A patent/KR101541558B1/ko not_active IP Right Cessation
- 2008-08-14 RU RU2010109542/04A patent/RU2492168C2/ru not_active IP Right Cessation
- 2008-08-14 NZ NZ583957A patent/NZ583957A/en not_active IP Right Cessation
- 2008-08-14 ES ES08789611T patent/ES2361463T3/es active Active
- 2008-08-14 MY MYPI2010000684A patent/MY153975A/en unknown
- 2008-08-14 DK DK08789611.4T patent/DK2195311T3/da active
- 2008-08-14 CA CA2695509A patent/CA2695509A1/en not_active Abandoned
- 2008-08-14 MX MX2010001881A patent/MX2010001881A/es active IP Right Grant
- 2008-08-14 DE DE602008005770T patent/DE602008005770D1/de active Active
- 2008-08-14 PL PL08789611T patent/PL2195311T3/pl unknown
- 2008-08-14 JP JP2010520670A patent/JP5451614B2/ja not_active Expired - Fee Related
- 2008-08-15 TW TW097131346A patent/TWI422373B/zh not_active IP Right Cessation
- 2008-08-19 AR ARP080103611A patent/AR067977A1/es not_active Application Discontinuation
-
2010
- 2010-03-12 MA MA32693A patent/MA31703B1/fr unknown
- 2010-03-16 ZA ZA2010/01873A patent/ZA201001873B/en unknown
- 2010-12-03 HK HK10111281.3A patent/HK1144809A1/xx not_active IP Right Cessation
-
2011
- 2011-05-30 CY CY20111100521T patent/CY1111830T1/el unknown
- 2011-06-16 HR HR20110449T patent/HRP20110449T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067977A1 (es) | Derivados de piridina y su uso como inmunomoduladores | |
AR070801A1 (es) | Derivados pirimidin -piridina | |
EA200600925A1 (ru) | Производные триазола в качестве антагонистов вазопрессина | |
AR079224A1 (es) | Compuestos insecticidas basados en derivados de isoxazolina | |
ECSP099638A (es) | Nuevo compuesto de adenina | |
TR200201752T2 (tr) | Dipeptid nitril katepsin K inhibitörleri. | |
PE20090042A1 (es) | Analogos de ciclopamina | |
AR041182A1 (es) | Derivados de fenoxipropenilfenilo y su uso como herbicidas | |
ATE506354T1 (de) | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR059178A1 (es) | Benzotiazoles heteroaril sustituidos, composiciones farmaceuticas que los contienen,y usos terapeuticos, entre ellos, en el tratamiento y/o prevencion de la enfermedad de alzheimer. | |
MX2007000035A (es) | Inhibidores de cetp. | |
DOP2010000046A (es) | Compuestos de biciclolactama sustituida | |
AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
AR076694A1 (es) | Benzoxazepinas como inhibidores de pi3k/m/tor, su uso en el tratamiento del cancer y su preparacion | |
AR067327A1 (es) | Derivados de piperidina / piperazina | |
AR047587A1 (es) | Moduladores del receptor de histamina-3 | |
AR038377A1 (es) | Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo) | |
AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
NO20042584L (no) | Dibenzylaminforbindelser og farmasoytisk anvendelse derav | |
HK1088607A1 (en) | Polycyclic agents for the treatment of respiratory syncytial virus infections | |
AR078775A1 (es) | Composicion farmaceutica que comprende un compuesto indol | |
AR079483A1 (es) | Inhibidores heterociclicos de la esfingosina quinasas, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos en enfermedades hiperproliferativas y/o inmunologicas. | |
AR059522A1 (es) | Arildihidroisoquinolinas sustituidas con aminoalcoholes, procedimiento para su preparacion y su uso como medicamentos | |
MY149400A (en) | Bridged six-membered ring compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |